Sotalol proarrhythmia: A report of five cases and an audit of the use of sotalol in a teaching hospital

Australian and New Zealand Journal of Medicine

Volumn 26, Issue 2, 1996, Pages 167-170

  Basta, M N ^a   Leitch, J W ^a   Fletcher, P J ^a  

^a JOHN HUNTER HOSPITAL   (Australia)

Author keywords

audit of sotalol use; sotalol proarrhythmia

Indexed keywords

CREATININE; SOTALOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; ELECTROCARDIOGRAM; FEMALE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MEDICAL AUDIT; RISK FACTOR; TORSADE DES POINTES;

EID: 0029900490     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1996.tb00880.x     Document Type: Article

References (10)

1. Ho DSW, Zecchin RP, Richards DAB, Uther JB, Ross DL. Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet 1994; 344: 18-23.
2. Mason JW, ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993; 329: 445-51.
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecanide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12.
4. Coplen SE, Antman EM, Berlin JA et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomised controlled trials. Circulation 1990; 82: 1106-16.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
6. Blair AD, Burgess ED, Maxwell BM, Cutler RE. Sotalol kinetics in renal insufficiency. Clin Pharmacol Ther 1981; 29:547-63.
7. Antonaccio LM, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol. Am J Cardiol 1990; 65: 12A-21A.
8. Physicians desk reference, Medical Economics Data Production Company, Montvale, NJ: 1994: 593-4.
9. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7.
10. Haverkamp W, Hordt M, Chen X et al. Torsades de pointes induced by D,L-sotalol. Circulation 1993; 88: 1-397.